Skip to main content
Premium Trial:

Request an Annual Quote

Eurofins Wins $30M Air Force Contract to Expand Capacity for COVID-19 Test Reagents

NEW YORK – The US Department of the Air Force and the Department of Health and Human Services awarded Eurofins Genomics US a $30 million contract to build a new production facility and to expand manufacturing capacity for the reagents used in COVID-19 diagnostic tests.

The new facility will focus on producing GMP-grade DNA, used in all PCR-based COVID-19 tests.

These DNA species, also known as oligos, are a key testing reagent but are vulnerable to supply shortages and manufacturers can face capacity constraints during peaks in demand, as has occurred throughout the pandemic. Eurofins' partnership with DAF and HHS aims to address that constraint.

The new facility will be located in Louisville, Kentucky, next to the company's US logistical hub. The proximity of the two facilities is expected to facilitate the fast and reliable distribution of reagents across the country.

Eurofins has been active in COVID-19 testing, having recently added SARS-CoV-2 mutation detection capabilities to its RT-PCR-based COVID-19 testing kit.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.